PI
NTLA icon

Putnam Investments’s Intellia Therapeutics NTLA Stock Holding History

Putnam Investments’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-56,513
Closed -$3.16M – 1172
2022
Q3 		$3.16M Buy
56,513
+795
+1% +$49.3K 0.01% 594
2022
Q2 		$2.88M Buy
55,718
+10,385
+23% +$527K 0.01% 669
2022
Q1 		$3.29M Buy
45,333
+915
+2% +$77.5K 0.01% 711
2021
Q4 		$5.25M Buy
44,418
+8,045
+22% +$1.01M 0.01% 515
2021
Q3 		$4.88M Buy
36,373
+1,127
+3% +$171K 0.01% 526
2021
Q2 		$5.71M Buy
+35,246
New +$2.74M 0.01% 487

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Putnam Investments's NTLA Position: Q4 2022 in Review

Putnam Investments sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 56,513 shares — an estimated $3.16M sold.

Putnam Investments first reported a position in NTLA in Q2 2021 and held it in 6 quarters. The position peaked at $5.71M in Q2 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Putnam Investments reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Putnam Investments sold 56,513 Intellia Therapeutics shares in Q4 2022, an estimated $3.16M.
  • Putnam Investments first reported a position in Intellia Therapeutics in Q2 2021 and held it in 6 quarters.
  • Putnam Investments's Intellia Therapeutics position peaked at $5.71M in Q2 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Putnam Investments's 13F filing for Q4 2022, filed 14 Feb 2023.